Cargando…
Long-Term Safety and Efficacy of Mirogabalin for Central Neuropathic Pain: A Multinational, Phase 3, 52-Week, Open-Label Study in Asia
INTRODUCTION: Central neuropathic pain (CNeP) is difficult to treat and has diverse etiology, including spinal cord injury (CNePSCI), Parkinson’s disease (CNePPD), and central post-stroke pain (CPSP). The safety and efficacy of mirogabalin have been demonstrated in short-term trials, including patie...
Autores principales: | Ushida, Takahiro, Katayama, Yoichi, Hiasa, Yoichi, Nishihara, Makoto, Tajima, Fumihiro, Katoh, Shinsuke, Tanaka, Hirotaka, Maeda, Takeshi, Furusawa, Kazunari, Kakehi, Yoshihiro, Kikumori, Kunika, Kuroha, Masanori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290008/ https://www.ncbi.nlm.nih.gov/pubmed/37115464 http://dx.doi.org/10.1007/s40122-023-00513-1 |
Ejemplares similares
-
Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Asia
por: Ushida, Takahiro, et al.
Publicado: (2023) -
Long‐term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain
por: Baba, Masayuki, et al.
Publicado: (2019) -
Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double‐blind, placebo‐controlled phase III study in Asian patients
por: Baba, Masayuki, et al.
Publicado: (2019) -
Results of Mirogabalin Treatment for Diabetic Peripheral Neuropathic Pain in Asian Subjects: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Study
por: Baba, Masayuki, et al.
Publicado: (2020) -
Therapeutic Effect of Mirogabalin on Peripheral Neuropathic Pain due to Lumbar Spine Disease
por: Kim, Kyongsong, et al.
Publicado: (2021)